CRA Financial Services LLC cut its holdings in shares of Amgen Inc. (NASDAQ: AMGN – Get Rating) by 9.1% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,196 shares of the medical research company stock after selling 120 shares during the period. CRA Financial Services LLC’s holdings in Amgen were worth $ 289,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Pacifica Partners Inc. raised its stake in Amgen by 7.1% during the first quarter. Pacifica Partners Inc. now owns 601 shares of the medical research company stock worth $ 137,000 after purchasing an additional 40 shares during the period. Gryphon Financial Partners LLC raised its stake in Amgen by 4.4% during the fourth quarter. Gryphon Financial Partners LLC now owns 1,040 shares of the medical research company stock worth $ 234,000 after purchasing an additional 44 shares during the period. Formidable Asset Management LLC raised its stake in Amgen by 1.9% during the fourth quarter. Formidable Asset Management LLC now owns 2,376 shares of the medical research company stock worth $ 541,000 after purchasing an additional 45 shares during the period. Sierra Capital LLC raised its stake in Amgen by 7.1% during the fourth quarter. Sierra Capital LLC now owns 678 shares of the medical research company stock worth $ 153,000 after purchasing an additional 45 shares during the period. Finally, Samalin Investment Counsel LLC raised its stake in shares of Amgen by 5.2% in the 4th quarter. Samalin Investment Counsel LLC now owns 932 shares of the medical research company stock valued at $ 210,000 after acquiring an additional 46 shares during the period. Hedge funds and other institutional investors own 79.01% of the company stock.
In other news, EVP Jonathan P. Graham sold 13,500 shares of the company stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $ 241.81, for a total value of $ 3,264,435.00. Following the completion of the transaction, the executive vice president now owns 37,333 shares in the company, valued at approximately $ 9,027,492.73. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director R Sanders Williams sold 600 shares of the company stock in a transaction on Monday, May 23rd. The shares were sold at an average price of $ 250.00, for a total transaction of $ 150,000.00. Following the completion of the transaction, the director now owns 5,501 shares of the company stock, valued at approximately $ 1,375,250. The disclosure for this sale can be found here. Insiders own 0.46% of the company stock.
NASDAQ AMGN opened at $ 245.37 on Friday. The company has a quick ratio of 1.09, a current ratio of 1.44 and a debt-to-equity ratio of 39.31. Amgen Inc. has a 52 week low of $ 198.64 and a 52 week high of $ 258.45. The stock has a market capitalization of $ 131.08 billion, a PE ratio of 24.15, a price-to-earnings-growth ratio of 2.10 and a beta of 0.57. The firm has a 50 day moving average of $ 244.23 and a two-hundred day moving average of $ 235.32.
Amgen (NASDAQ: AMGN – Get Rating) last posted its quarterly earnings results on Wednesday, April 27th. The medical research company reported $ 4.25 EPS for the quarter, topping the consensus estimate of $ 4.22 by $ 0.03. Amgen had a net margin of 21.75% and a return on equity of 165.95%. The company had revenue of $ 6.24 billion during the quarter, compared to analysts’ expectations of $ 6.09 billion. During the same quarter in the previous year, the business posted $ 3.70 EPS. On average, equities research analysts expect that Amgen Inc. will post 17.44 earnings per share for the current fiscal year.
A number of equities research analysts have recently issued reports on the stock. StockNews.com raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research note on Monday, May 16th. BMO Capital Markets reduced their price target on shares of Amgen from $ 263.00 to $ 243.00 in a research note on Thursday, April 28th. Piper Sandler boosted their price target on shares of Amgen from $ 255.00 to $ 260.00 in a research note on Thursday, April 28th. TheStreet downgraded shares of Amgen from a “b +” rating to a “c +” rating in a research note on Wednesday, April 27th. Finally, Mizuho boosted their price target on shares of Amgen from $ 202.00 to $ 208.00 in a research note on Tuesday, May 10th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $ 242.57.
Amgen Company Profile: (Get Rating)
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology / hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due to a low white blood cell count in cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ: AMGN – Get Rating).
Receive News & Ratings for Amgen Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amgen and related companies with MarketBeat.com’s FREE daily email newsletter.